PK-PD modeling of protein drugs: Implications in assay development

Bioanalysis

Volumn 3, Issue 6, 2011, Pages 659-675

  Roskos, Lorin K ^a   Schneider, Amy ^a   Vainshtein, Inna ^a   Schwickart, Martin ^a   Lee, Rozanne ^a   Lu, Hong ^a   Faggioni, Raffaella ^a   Liang, Meina ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN;

ANALYTIC METHOD; BIOASSAY; CELL SURFACE; CONFOCAL MICROSCOPY; DISSOCIATION CONSTANT; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISPOSITION; DRUG EXPOSURE; GENE EXPRESSION PROFILING; GOOD LABORATORY PRACTICE; INTERNALIZATION; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MEDICAL RESEARCH; MICHAELIS MENTEN KINETICS; PHARMACODYNAMICS; PHARMACOKINETICS; QUANTITATIVE ANALYSIS; REVIEW; SIMULATION;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; PROTEINS;

EID: 79953126598     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.28     Document Type: Review

References (41)

1. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm. Res. 22(9), 1432-1437 (2005). (Pubitemid 41215882)
2. Roskos LK, Ren S, Robbie G. Application of modeling and simulation in the development of protein drugs. In:Clinical Trial Simulations. Kimko HHC, Peck CC (Eds). Springer Science and Business Media, LLC, NJ, USA 361-396 (2011).
3. Mager DE , Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn. 28(6), 507-532 (2001). (Pubitemid 34289541)
4. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 11(1-2), 81-88 (2006). (Pubitemid 43227856)
5. Yang J, Ng C, Lowman H et al. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a generic immunoglobulin pharmacokinetic (GRIP) assay. J. Immunol. Methods 335(1-2), 8-20 (2008).
6. Thway T, Macaraeg C, Calamba D et al. Applications of a planar electrochemiluminescence platform to support regulated studies of macromolecules: Benefits and limitations in assay range. J. Pharm. Biomed. Anal. 51(3), 626-632 (2010).
7. Oh CK, Faggioni R, Jin F et al. An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. Br. J. Clin. Pharmacol. 69(6), 645-655 (2010).
8. Baselga J, Pfister D, Cooper MR et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18(4), 904-914 (2000). (Pubitemid 30106623)
9. Fracasso PM, Burris H, III, Arquette MA et al. A Phase I escalating single-dose and weekly fixed-dose study of cetuximab: Pharmacokinetic and pharmacodynamic rationale for dosing. Clin. Cancer Res. 13(3), 986-993 (2007). (Pubitemid 46340377)
10. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol. 22(15), 3003-3015 (2004). (Pubitemid 41103711)
11. Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat. Biotechnol. 25(10), 1134-1143 (2007). (Pubitemid 47542248)
12. Yang BB, Lum P, Chen A et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin. Pharmacokinet. 49(11), 729-740 (2010).
13. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br. J. Clin. Pharmacol. 63(5), 548-561 (2007). nn Example of simultaneous pharmacokinetic-pharmacodynamic (PK-PD) modeling of free dug levels and free and total target levels. (Pubitemid 46632569)
14. Betts AM, Clark TH, Yang J et al. The application of target information and preclinical pharmacokinetic/ pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J. Pharmacol. Exp. Ther. 333(1), 2-13 (2010). n Application of PK-PD modeling of PK and soluble ligand levels during drug discovery.
15. Conway BR, Minor LK, Xu JZ et al. Quantification of G-protein coupled receptor internatilization using G-protein coupled receptor-green fluorescent protein conjugates with the ArrayScan® high-content screening system. J. Biomol. Screen 4(2), 75-86 (1999). (Pubitemid 29278955)
16. Perera RM, Zoncu R, Johns TG et al. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: A novel anti-epidermal growth factor receptor antibody. Neoplasia 9(12), 1099-1110 (2007). (Pubitemid 350255358)
17. Nordberg E, Friedman M, Gostring L et al. Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl. Med. Biol. 34(6), 609-618 (2007). (Pubitemid 47248288)
18. Gostring L, Chew MT, Orlova A et al. Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. Int. J. Oncol. 36(4), 757-763 (2010).
19. Mazor Y, Barnea I, Keydar I, Benhar I. Antibody internalization studied using a novel IgG binding toxin fusion. J. Immunol. Methods 321(1-2), 41-59 (2007). (Pubitemid 46441195)
20. Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target-mediated drug disposition model and identifiability of model parameters. J. Pharmacokinet. Pharmacodyn. 35(5), 573-591 (2008).
21. Geiseler D , Ritter M. Effect of sample dilution on measurements of free (unbound) hormones. Clin. Chem. 30(1), 28-32 (1984). (Pubitemid 14222554)
22. Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1b in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206(5), 1029-1036 (2009). nn Excellent example of linking PK and target modulation to clinical end points by PK-PD modeling.
23. Devine SM, Flomenberg N, Vesole DH et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J. Clin. Oncol. 22(6), 1095-1102 (2004). (Pubitemid 41095043)
24. Stewart DA, Smith C, MacFarland R, Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol. Blood Marrow Transplant. 15(1), 39-46 (2009).
25. Lacy MQ, Alsina M, Fonseca R et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J. Clin. Oncol. 26(19), 3196-3203 (2008).
26. Bauer RJ, Dedrick RL, White ML, Murray MJ, Garovoy MR. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J. Pharmacokinet. Biopharm. 27(4), 397-420 (1999). (Pubitemid 30228022)
27. Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ. Pharmacokinetic- pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm. Res. 22(7), 1088-1100 (2005). (Pubitemid 41127066)
28. Mutsaers AJ, Francia G, Man S et al. Dose-dependent increases in circulating TGF-a and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin. Cancer Res. 15(7), 2397-2405 (2009).
29. Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 92(6), 857-858 (2007). (Pubitemid 350155317)
30. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of b-cell function. N. Engl. J. Med. 361(22), 2143-2152 (2009).
31. Kreitman RJ, Wilson WH, Bergeron K et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapyresistant hairy-cell leukemia. N. Engl. J. Med. 345(4), 241-247 (2001). (Pubitemid 32695063)
32. Kim YH, Duvic M, Obitz E et al. Clinical efficacy of zanolimumab (HuMax-CD4): Two Phase II studies in refractory cutaneous T-cell lymphoma. Blood 109(11), 4655-4662 (2007). (Pubitemid 46827755)
33. Roskos LK, Lum P, Lockbaum P, Schwab G, Yang BB. Pharmacokinetic/ pharmacodynamic modeling of pegfilgrastim in healthy subjects. J. Clin. Pharmacol. 46(7), 747-757 (2006). n Example of dose- and time-dependent PK caused by effects of drug on the target cell population, and the application of a mechanistic PK-PD model. (Pubitemid 43882798)
34. Bonilla L, Means G, Lee K, Patterson S. The evolution of tools for protein phosphorylation site analysis: From discovery to clinical application. Biotechniques 44(5), 671-679 (2008). (Pubitemid 351656288)
35. Dahl ME, Berson A, Lora J, Fuentes M. A novel CCR5-specific pharmacodynamic assay in whole blood using phosphoflow cytometry highlights different ligand-dependent responses but similar properties of antagonists in CD8+ and CD4+ T lymphocytes. J. Pharmacol. Exp. Ther. 327(3), 926-933 (2008).
36. Yao Y, Richman L, Higgs BW et al. Neutralization of interferon-a/b- inducible genes and downstream effect in a Phase I trial of an anti-interferon-a monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60(6), 1785-1796 (2009).
37. Yao Y, Higgs BW, Morehouse C et al. Development of potential pharmacodynamic and diagnostic markers for anti-IFN-a monoclonal antibody trials in systemic lupus erythematosus. Hum. Genomics Proteomics DOI: 10.4061/2009/374312 (2009) (Epub only). n Development of a PD biomarker assay based on gene expression profiling.
38. Arai M, Jain S, Weaver AA et al. Development and application of a biomarker assay for determining the pharmacodynamic activity of an antagonist candidate biotherapeutic antibody to IL21R in whole blood. J. Transl. Med. 8, 51 (2010).
39. Vugmeyster Y, Allen S, Szklut P et al. Correlation of pharmacodynamic activity, pharmacokinetics, and antiproduct antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys. J. Transl. Med. 8, 41 (2010).
40. Bissonnette R, Papp K, Maari C et al. A randomized, double-blind, placebocontrolled, Phase I study of MEDI-545, an anti-interferon-a monoclonal antibody, in subjects with chronic psoriasis. J. Am. Acad. Dermatol. 62(3), 427-436 (2010).
41. Abraham AK, Kagan L, Kumar S, Mager DE. Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-b in mice. J. Pharmacol. Exp. Ther. 334(1), 327-332 (2010).